Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers Academic Article uri icon


MeSH Major

  • Adenocarcinoma
  • Biomarkers, Tumor
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms


  • The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.

publication date

  • July 2013



  • Academic Article



  • eng

PubMed Central ID

  • PMC3695315

Digital Object Identifier (DOI)

  • 10.1007/s12094-012-0983-z

PubMed ID

  • 23359174

Additional Document Info

start page

  • 503

end page

  • 8


  • 15


  • 7